eFFECTOR Therapeutics, Inc. (EFTR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -35.81 Million USD | -177.02% |
| 2022 | -12.92 Million USD | -181.83% |
| 2021 | 15.79 Million USD | 11.17% |
| 2020 | 14.21 Million USD | 147.79% |
| 2019 | -29.73 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -8.83 Million USD | 3.23% |
| 2023 Q3 | -8.3 Million USD | 0.73% |
| 2023 FY | -35.81 Million USD | -177.02% |
| 2023 Q4 | -9.12 Million USD | -9.95% |
| 2023 Q2 | -8.36 Million USD | 16.48% |
| 2023 Q1 | -10.01 Million USD | -8.14% |
| 2022 Q4 | -9.26 Million USD | 3.13% |
| 2022 Q1 | 3.06 Million USD | -83.89% |
| 2022 Q3 | -9.55 Million USD | -38.24% |
| 2022 FY | -12.92 Million USD | -181.83% |
| 2022 Q2 | -6.91 Million USD | -325.32% |
| 2021 FY | 15.79 Million USD | 11.17% |
| 2021 Q3 | 8.87 Million USD | 260.04% |
| 2021 Q2 | -5.54 Million USD | 15.71% |
| 2021 Q1 | -6.58 Million USD | -1557.93% |
| 2021 Q4 | 19.04 Million USD | 114.54% |
| 2020 Q3 | -7.6 Million USD | -202.33% |
| 2020 Q4 | -397 Thousand USD | 94.78% |
| 2020 FY | 14.21 Million USD | 147.79% |
| 2020 Q1 | 736 Thousand USD | 0.0% |
| 2020 Q2 | 7.43 Million USD | 910.33% |
| 2019 FY | -29.73 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -4603.186% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -314.863% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | -16.462% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 71.147% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -122.733% |
| Better Therapeutics, Inc. | -39.76 Million USD | 9.932% |
| Calithera Biosciences, Inc. | -18.86 Million USD | -89.818% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | -94.858% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 0.704% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 68.731% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -1492.832% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 52.095% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 39.388% |
| Innovation1 Biotech Inc. | -5.98 Million USD | -498.02% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | -68.174% |
| Molecular Templates, Inc. | -8.12 Million USD | -340.805% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -135.953% |
| NexImmune, Inc. | -32.34 Million USD | -10.718% |
| Orgenesis Inc. | -55.36 Million USD | 35.314% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | -41.753% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -45801.534% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | -95.798% |
| Scopus BioPharma Inc. | -11.6 Million USD | -208.454% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 93.749% |
| Statera Biopharma, Inc. | -174.4 Million USD | 79.467% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -898.077% |
| Trevena, Inc. | -40.28 Million USD | 11.115% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -62799.146% |
| Vaccinex, Inc. | -20.25 Million USD | -76.836% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -2929.408% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 29.862% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -360.462% |